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Abstract Rheumatoid arthritis (RA) is a common autoim-
mune disease characterized by persistent inflammation of
joints resulting in progressive destruction of cartilage and
bone. Recently, biological agents that suppress the activities
of proinflammatory cytokines have shown efficacy as anti-
rheumatic drugs, but require frequent administration, and
often result in systemic immune suppression. Thus, gene
transfer approaches are being developed as an alternative
approach for targeted, more efficient, and sustained deliv-
ery of inhibitors of inflammatory cytokines as well as other
therapeutic agents. Several gene therapy approaches have
been established in preclinical animal models. In these
models, autoantigen-specific T cells have been demon-
strated to be ideal gene delivery vehicles for the local deliv-
ery of “immunoregulatory molecules” because these cells
have tissue-specific homing and retention properties. In-
deed, bioluminescence studies in an animal model of
inflammatory arthritis revealed that these cells accumulated
in and remained in inflamed joints. Transfer of genetically
modified dendritic cells (DCs) may also have interesting
effects. We conclude that modifying antigen-specific T cells
or autologous DCs by retroviral transduction for local ex-
pression of regulatory proteins is a promising therapeutic
strategy for the treatment of RA.
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Introduction
Rheumatoid arthritis (RA) is an autoimmune disease char-
acterized by the infiltration of various leukocyte subpopula-
tions into both the developing pannus and synovial space.
The chronic nature of this disease results in multiple joint
inflammation with subsequent destruction of joint and car-
tilage and erosion of bone. The exact pathogenesis of RA
remains largely elusive; however, cumulative evidence has
suggested that T-cell-mediated autoimmune responses play
a crucial role in the pathogenesis of RA.1 Autoantigens that
lead to autoimmune arthritis have not been identified,
clonotypic analysis of T-cell receptors (TCR) from infiltrat-
ing T cells in synovial tissue suggests the existence of an
autoantigen recognized by autoreactive T cells.2 Although
there are many drugs on the market that alleviate some of
the abnormal immune responses, including T-cell functions
associated with autoimmune arthritis, current treatments
for RA often result in nonspecific toxicity and systemic
immune suppression. The local delivery of “regulatory
proteins” that can modulate an autoimmune response
would be a desirable new approach for the treatment of
RA. Autoantigen-specific T cells have tissue-specific hom-
ing properties, suggesting that these cells may be ideal ve-
hicles for the local delivery of “immunoregulatory
molecules”. This review focuses on the potential therapeu-
tic utility of immune cells, mainly autoantigen-specific T
cells, as gene delivery vehicles that locally manipulate the
abnormal immune response in RA.
Current therapeutic strategies for the treatment of
rheumatoid arthritis
Because the etiology of RA is unknown, the treatment op-
tions remain limited. The goal of current therapies for RA
is elimination of joint pain by the inhibition of chronic
inflammation, and improvement of the activity of daily liv-
ing by the suppression of joint destruction.3 Although non-
steroidal antiinflammatory drugs (NSAIDs) are frequently
prescribed as an antiinflammatory, the joint destruction is
not inhibited by the use of NSAIDs. Treatment of RA has
been improved with the advent of disease-modifying anti-
rheumatic drugs (DMARDs) such as methotrexate (MTX),
sulfasalazine, and others. However, it is still difficult to sup-
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press the progression of joint destruction even by the use of
DMARDs. Recent advances in the field of immunology and
rheumatology have revealed that inflammatory cytokines
such as tumor necrosis factor (TNF), interleukin (IL)-1β,
and IL-6 play crucial roles in the synovial inflammation in
RA. Therefore, to increase the specificity of therapies for
RA, emphasis has shifted to targeting cytokines and their
receptors. Neutralization of pro-inflammatory cytokines
by monoclonal antibodies (mAbs) or soluble receptors
can efficiently control RA.4–7 Importantly, unlike usual
DMARDs, joint destruction has been shown to be
significantly suppressed by TNF blockade. Thus, modula-
tion of cytokine balance is a promising strategy for control-
ling RA. However, arthritis therapies that employ
biological agents are currently limited by possible systemic
side effects such as the occurrence and re-emergence of
viral and bacterial infections, as well as their exorbitant
expense. Most importantly, the best of current regimens still
fail to help a significant percentage of patients with severe,
destructive disease. As a result of the clear need for alterna-
tive, novel therapies for treating arthritis, gene transfer has
been evaluated as an approach to circumvent the inherent
impediments associated with delivery of therapeutic
proteins.
Role of T cells in rheumatoid arthritis
It is well accepted that CD4+ T cells play a critical role in the
pathogenesis of several autoimmune diseases including
RA.1 Therefore, therapeutic strategies have focused on the
modulation of CD4+ T cells. Depletion of CD4+ T cells was
effective in treating a mouse model of RA, type II collagen
(CII)-induced arthritis.8 Unfortunately, the same treatment
seemed less effective in human RA.9 Furthermore, a recent
experiment has raised the question of whether T cells con-
tribute to the pathogenesis of collagen-induced arthritis.10
There is a continuing argument on the involvement of T
cells in the pathogenesis of RA. Several reports have indi-
cated that the major pathogenic factors in RA involve the
macrophage and fibroblast-like synovial cells.11 There is
significant supporting evidence for such a hypothesis, and
most inflammatory events, which include joint destruction,
are clearly mediated by these cells. Nevertheless, the pro-
duction of significant amounts of T-cell-derived cytokines,
the major histocompatibility complex (MHC) association
with RA, and the response to therapies directed or partly
directed at T cell, such as cyclosporine A, tacrolimus and
leflunomide, suggest that the involvement of T cells in the
pathogenic process can not be easily abandoned. Further
support for such involvement stems from data showing the
involvement of cell contact between T cells and macro-
phages as one mechanism for the secretion of pro-
inflammatory cytokines.12 Recent observations in the course
of clinical trials seem to support the notion of a potential
role of T cells in the initiation and perpetuation of RA. A
fusion protein comprised of CTLA4 fused to an immuno-
globulin Fc portion (CTLA-4Ig), which binds to the
costimulatory molecules B7-1 (CD80) and B7-2 (CD86)
and thus prevents CD28/B7 interaction and subsequent ac-
tivation of the CD28 receptor on T cells, appears to be
highly effective in treating RA.13 Although these data will
have to be confirmed in further trials, not only do these
results suggest that therapies directed at interfering with T-
cell activities may be as effective as other DMARDs, but
also that T cells are involved in the pathogenesis of RA.
Autoantigen-specific CD4+ T cells can transfer organ-
specific autoimmune disease in mice, and CD4+ T cells can
be found in target organs in both human and mouse models
of autoimmunity; thus, autoantigen-specific CD4+ T cells
have tissue-specific homing properties. In fact, it has been
reported that T cells that express specific chemokine recep-
tor were found in the synovial tissue of RA patients.14,15
These results also raise the possibility that arthritogenic
CD4+ T cells, retrovirally transduced to express immuno-
regulatory proteins, may be ideal candidates for the local
“gene therapy”.
Autoantigen-specific T-cell-mediated gene therapy in
rheumatoid arthritis
Local gene transfer approaches are being developed as an
alternative approach for targeted, more efficient and sus-
tained delivery of inhibitors of abnormal immune re-
sponses. There are several different approaches that can be
utilized for the treatment of arthritis.16,17 The first approach
involves the direct injection of the vector at the site where
expression is needed, allowing genetic modification of cells
following injection (Fig. 1c). The second approach involves
the genetic manipulation of cells such as fibroblast or syn-
ovial cells in culture followed by injection of the modified
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Fig. 1. Approaches and vectors
used for local gene transfer to
joints. IL, interleukin; HSV,
herpes simplex virus; AAV,
adeno-associated virus
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cells locally such as intra-articular injection (Fig. 1b). How-
ever, the possibility of treating each affected joint may
prove difficult in a clinical setting because of the number of
joints involved. Hence, alternative approaches have been
developed to deliver therapeutic agents. Localized gene
delivery of a preselected amount of a regulatory protein to
a specific site should ensure maximum therapeutic effect in
the area of inflammation while minimizing the exposure of
nontargeted organs to the gene products, and markedly
reducing the risk of undesirable systemic side effects (Fig.
1a). Antigen-specific CD4+ T cells and T-cell hybridomas
have been used to deliver immunoregulatory cytokines and
cytokine inhibitors to autoimmune lesions, showing that T
cells are suitable vehicles for targeted immunotherapy.18,19
We and others have demonstrated effective prevention
of collagen-induced arthritis (CIA), an animal models of
rheumatoid arthritis, by adoptive cellular gene therapy
using autoantigen-specific T cells and T-cell hybridomas
retrovirally transduced to express IL-12/23 receptor blocker
IL-12p40,20 the regulatory cytokine IL-4,21 and TNF-antago-
nizing anti-TNF scFv.22 Amelioration of autoimmune ar-
thritis by antigen-specific immunoregulatory proteins such
as IL-12p40 and/or IL-4-transduced CD4+ T cells was due to
local delivery of immunoregulatory protein to the inflamed
joint. This was demonstrated by three points as follows.
First, analysis of the cytokine profile, isotype profiles of
antitype II collagen antibodies, and the proliferative re-
sponses to antigen of draining lymph node cells and spleen
cells was unaffected in the treatment groups compared with
untreated and vector-only treated animals. This finding is
also consistent with a good safety profile of the adoptive
cellular gene therapy approach in terms of low systemic side
effects. Second, antigen recognition was required by the
transduced T cells to ameliorate CIA. To this effect, when
retrovirally transduced CII-reactive and MBP-reactive T-
cell hybridomas that express equivalent amounts of im-
mune regulatory protein were injected into both CIA and
experimental autoimmune encephalomyelitis (EAE) mice,
only CII-reactive T-cell hybridomas were therapeutic in
CIA and only MBP-reactive T cells were therapeutic in
EAE.20,23 Interestingly, both cell types were found to mi-
grate to inflamed paws as confirmed by in vivo real-time
bioluminescence imaging and polymerase chain reaction
(PCR) detection of YFP marker mRNA in joint tissue
homogenates. However, bioluminescence imaging showed
that only CII-specific cells persisted in the inflammatory
lesions, while the homing of MBP-specific cells was tran-
sient. Of note, the CII-specific cells persisted in the joints
long-term because YFP mRNA could be detected by PCR
up to 55 days after adoptive cell transfer. Based on the
chemokine receptor expression profile of our antigen-
specific T-cell hybridomas and their ability to migrate in
vitro in response to chemokines that were found to be ex-
pressed in inflamed joints in CIA,21 we hypothesize that
these vehicle cells home to sites of inflammation by means
of chemotaxis independent of their antigen specificity. Re-
tention in inflammatory lesions, however, occurs only upon
recognition of antigen by the specific T-cell receptor (TCR).
Third, PCR analysis of joint tissue homogenates showed
that in animals that received anti-TNF scFv expressing T-
cell hybridomas, IL-6 transcription was suppressed.22 Taken
together, these results strongly suggest that T cell-mediated
adoptive cellular gene therapy works based on site-specific
homing and retention of the vehicle cells and local effects of
the delivered immune-modulating molecules.
Previous barriers of retroviral transduction for the appli-
cation of gene therapy have included low proviral integra-
tion frequency in immune cells, proviral promoter
shutdown, and inadequate isolation and expansion of trans-
duced cells. In fact, only 3%–5% transduction efficiency
was obtained in previous studies using retrovirus-mediated
TGF-β or IL-10 gene transduction into T cells.24,25 However,
Costa et al. have developed a novel retroviral construct that
contains an internal ribosomal entry site (IRES).26 This
bicistronic expression vector allows coexpression of two
genes, the gene of interest and a fluorescent-marker-
encoding gene on one mRNA transcript. Using this novel
construct we and others have been able to stably and dura-
bly transduce primary T cells and T-cell hybridomas with up
to 80% transduction efficiency that has made retroviral-
mediated adoptive T-cell-mediated gene therapy easier in
murine models of autoimmune disease. Adoptive T cell-
mediated gene therapy may have great advantages over
other gene delivery tools for treating autoimmunity because
autoantigen reactive T cells can target the inflamed
autoantigen-expressing tissues, while other methods of
gene transfer such as adenovirus-mediated gene therapy
may be limited by strong immunogenicity, making repeated
injections difficult.27
However, potential problems of autoantigen-specific T-
cell-mediated retrovirus gene therapy remain to be solved.
For instance, in the clinical setting, autoantigen-specific T
cells are not easy to obtain because the autoantigen may
differ in different patients and may change with time in the
same patient due to epitope spreading. To circumvent these
potential problems, T cells could be engineered to recog-
nize a joint antigen with an appropriate MHC restriction via
TCR gene transfer to obtain artificial autoreactive T
cells.28,29 A recent clinical trial has raised the serious ques-
tion of retrovirus-mediated gene therapy. Hacein-
Bey-Abina et al. reported that uncontrolled exponential
clonal proliferation of mature T cells has occurred in pa-
tients who had retrovirus-mediated gene therapy.30 There-
fore, new challenges are needed to develop even more
specific gene therapy interventions.
Candidate molecules to generate regulatory T cells by
gene transduction
Numerous studies have demonstrated successful prevention
or amelioration of autoimmune diseases by blocking T-cell-
derived cytokines with specific antagonists or by counter-
acting the inflammatory response with immune regulatory
cytokines. Systemic administrations of TGF-β, interleukin-1
receptor antagonist (IL-1β), IL-4, IL-10, IL-12p40, anti-IL-
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15, anti-IL-17, or anti-TNF serve as effective therapies in
models of autoimmune disease such as CIA.31,32 Some of
these protocols appear to work by shifting the cytokine
balance away from Th1 dominance. Indeed, cytokine-
induced immune deviation has been investigated as
potential therapy for autoimmune diseases because
cytokines present at the time of activation may alter the
pathogenicity of effector T cells.33,34 These results suggest
that antiinflammatory cytokines or specific antagonists of T-
cell-derived cytokines would be good candidates for anti-
gen-specific T-cell-mediated gene therapy.
A still growing body of evidence has demonstrated that
specific T-cell populations that have suppressive/regulatory
properties (Tregs) tightly control autoaggressive immune
responses. Therefore, generation of Treg by gene introduc-
tion would be a novel cell-mediated therapy for autoim-
mune arthritis. Among the CD4+ Treg cells basically two
different subsets of Treg cells can be differentiated by their
distinct suppressive mechanisms. The suppressive capacity
of the first subset, Th3 and type 1T regulatory (Tr1) cells, is
contact independent and is based mainly on cytokines such
as IL-10 and TGF-β.35,36 The possibility of using one or the
other of these two cytokines as candidates was described
above. The second T-cell subset with suppressive functions
that limits the outcome of autoimmune responses, was de-
scribed as a subset of peripheral CD4+ T cells, which co-
express CD25, that is critical for the control of autoreactive
T cells in vivo.37,38 Naturally occurring CD4+CD25+ Treg
cells exert their suppressive effects obviously via cell con-
tact by membrane-bound molecules although the nature of
these molecules is still elusive. CD4+CD25+ Treg cells are
characterized by the constitutive expression of several acti-
vation markers including CTLA-4 (CD152),39 glucocorti-
coid-induced TNFR (GITR) family-related protein,40
membrane-bound TGF-β, OX40 (CD134),41 and L-selectin
(CD62L).42
Regarding the development and function of CD4+CD25+
Treg cells, the transcription factor FoxP3 was found to play
a key role.43 Originally, it was demonstrated that mice ex-
pressing a naturally occurring loss-of-function mutation
of FoxP3 (scurfy mice) rapidly develop a fatal
lymphoproliferative disease similar to that seen in mice
lacking CTLA-4 or TGF-β.44 FoxP3 is exclusively expressed
in murine CD4+CD25+ Treg cells and ectopic expression
of FoxP3 in conventional CD4+CD25− cells conferred sup-
pressor function to this T-cell subset. Recently,
Anandasabapathy et al. have identified a new gene named
GRAIL (gene related to anergy in lymphocytes).45 They
have demonstrated that retrovirally transduced T-cell hy-
bridomas that expressed GRAIL showed a blockade in Il-2
transcription, and CD4+CD25+ Treg cells also express
GRAIL after activation (Ref. 46, and unpublished data).
The significance of these molecules with respect to the sup-
pressive properties of CD4+CD25+ Treg cells is currently
controversial; however, these molecules would be candi-
dates to generate antigen-specific regulatory T cells. Taken
together, these observations will provide several candidate
molecules for T-cell-mediated gene therapy of autoimmune
arthritis.
Using dendritic cells as gene delivery vehicles
A simple method for targeted gene delivery is the local
injection of either naked DNA or viral vectors into, for
example, inflamed joints. Interestingly, however, studies by
Lechman et al. in various models of arthritis show a remark-
able “contralateral effect” after intra-articular injection of
adenoviral vectors encoding antiinflammatory cytokines
and cytokine antagonists; that is, disease amelioration was
observed not only in the injected but also in the non-in-
jected contralateral joints.47 These authors suggested that
modified activity of DCs may be a possible mechanism un-
derlying this phenomenon. Therefore, DCs would also be a
good candidate to deliver immunoregulatory molecules.
Dendritic cells (DCs) are the most effective antigen-
presenting cells (APCs) in the induction of primary immune
responses.48 A growing understanding of heterogeneous
immunoregulatory functions of DCs prompted several in-
vestigators to consider DC-based immunotherapies for
autoimmune diseases. Genetic modification of DCs with
genes encoding immunoregulatory molecules is an attrac-
tive strategy for generation of immunoregulatory DCs. This
challenging approach has been tried for the control of al-
lograft rejection in transplantation where Fas ligand-trans-
duced DCs prolonged cardiac allograft survival in mice.49
In arthritis animal models, Kim et al. investigated the use
of genetically modified DCs in the therapy of autoimmune
disease.50 They demonstrated that intravenous injection
into mice with established CIA of immature DCs infected
with adenovirus encoding IL-4 resulted in almost complete
suppression of disease, with no recurrence of disease for up
to 4 weeks after treatment. These studies suggested that
DCs could prove to be powerful vehicles for effective, long-
term gene therapy of autoimmune disease. We have found
that DCs transduced to express either IL-12p40 or IL-10 are
also effective in suppressing CIA (Nakajima et al., unpub-
lished data). These data are in excellent agreement with
Morita et al., who demonstrated reduced CIA disease inci-
dence and severity by injecting bone marrow-derived DCs
retrovirally transduced to express IL-4 before disease
onset.51 These experiments raise the exciting possibility of
using DCs for adoptive cellular gene therapy of autoim-
mune disease. Regarding the mechanism of DC action,
adoptive transfer of IL-4-expressing DCs lead to suppres-
sion of Th1-type immune responses in the lymph nodes and
spleen and diminished the associated humoral immune re-
sponses. The authors concluded that the therapeutic DCs
migrated to the lymphoid tissues and modulated T-cell im-
mune responses by expression of the regulatory cytokine
IL-4 through specific DC–T-cell interactions. A recent
study demonstrated interesting results targeting the specific
DC–T-cell interactions. Transfer of DCs genetically engi-
neered to express TNF related apoptosis inducing ligand
(TRAIL) could inhibit CIA.52 These modified DCs induced
antigen-specific T-cell apoptosis by the interaction between
TRAIL on DC and TRAIL receptor expressed on T cells.
Our own studies of bone marrow-derived DC migration in
CIA using bioluminescence imaging suggested that DCs
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injected intravenously not only homed to lymphoid organs,
but also accumulated in inflamed joints and therefore could
be used to deliver antiinflammatory molecules directly to
the site of inflammation (Nakajima, unpublished data).
Taken together, these results indicate that the use of geneti-
cally engineered DCs is a very promising approach for
adoptive cellular gene therapy of autoimmune disease.
Bioluminescence imaging of immune cell trafficking
in vivo
Lymphocytes are highly mobile cells that travel throughout
the body in response to a tremendous variety of stimuli.
Understanding lymphocyte trafficking patterns in vivo is a
necessary prelude to adoptive cellular gene therapy. To
directly examine whether CII-specific T cells home to the
site of inflammation, we transduced a GFP-luciferase fusion
protein gene into CII-specific T-cell hybridomas and tested
the patterns of cell trafficking using whole body biolumines-
cence imaging of the labeled cells in living animals.20,21 This
novel technique has been used to monitor bacterial coloni-
zation and tumor cell growth in vivo and has demonstrated
excellent sensitivity,53,54 and should allow visualization of
the trafficking of antigen-specific CD4+ T cells in vivo.55
Before imaging, mice were anesthetized and received a so-
lution of the substrate luciferin into the peritoneal cavity
5min before imaging. The enzymatic reaction between lu-
ciferase and luciferin causes emissions of photons from
within the animal. Photons emitted from luciferase within
the animal, transmitted through the tissue were detected by
a cooled charge-coupled device camera. A pseudocolor im-
age representing light intensity of the emission is super-
imposed on a gray-scale body-surface reference image
collected under real illumination, and the data are acquired
and analyzed using appropriate software. This biolumines-
cence study revealed that antigen-specific “immuno-
regulatory protein”-producing cells inhibited CIA develop-
ment by homing to and remaining in the inflamed joints and
suppressing inflammation locally (Fig. 2).
Concluding remarks
The main challenge for gene therapy in arthritis is to be able
to provide a cost-effective long-term safe treatment that will
dramatically improve the current therapeutic outcomes
provided by protein therapy and provide for repair of joint
tissue and function. Retroviral-mediated adoptive cellular
gene therapy has been developed as an efficient novel strat-
egy for the therapy of RA. The clinical trials pioneered by
the group in Pittsburgh using autologous synoviocytes con-
stitutively expressing IL-1Ra from a retroviral vector dem-
onstrated that such approach is safe and feasible.56 Whether
such another ex vivo approach using these immobile cells
will ultimately lead to a long-term benefit needs further
investigation. Thus, antigen-specific T cells and DCs hold
promise as effective gene delivery vehicles for adoptive
cellular gene therapy as shown by our studies described
above. As a further step to enhance homing capacity, novel
engineered chemokine receptor-bearing cells that can more
specifically follow chemokine gradients to inflammatory le-
sions may be required in the future. Finally, some very
encouraging results have been obtained in studies combin-
ing various gene products and/or gene delivery strategies;
thus, future research should look further into additional
potential targets.
Stem cells have been proposed as potent therapeutic
means for tissue repair in arthritic disease.57 These cells
provide a new cell-mediated therapy for advanced RA.
While mesenchymal stem cells capable of differentiating
into cartilage and bone can be isolated from bone marrow
and be genetically manipulated in vitro, it will be necessary
to develop means to regulate their differentiation pathway
in vivo as well as assuring their homing to damaged areas
for appropriate repair. These cells may also need to be
engineered to stop the inflammatory reactions occurring in
the diseased joint and or directed at the transferred cells
themselves.
In conclusion, improved adoptive cellular gene therapy
delivering optimized combinations of immune-regulatory
molecules will undoubtedly be informative in characterizing
the underlying immune mechanisms in organ-specific
autoimmune diseases, and should lead to new therapeutic
options for treating human autoimmune diseases.
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